Grants and Contributions:
Title:
In vivo proof of concept study of Nuc-Nab gene editing complex targeting the KRAS oncogene
Agreement Number:
983780
Agreement Value:
$98,270.00
Agreement Date:
Dec 20, 2021 - Dec 30, 2022
Description:
Using a known oncogene as the target, this project will aim at generating a proof of concept in animal for a novel gene editing therapeutic platform. Using a proprietary targeting mechanism, prior to the proposed project, in vitro demonstrations with very encouraging results were obtained.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4W 1K7
Reference Number:
172-2021-2022-Q3-983780
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
701783482
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 70 days.
Amendment Date
Sep 1, 2022
Recipient's Legal Name:
Jenthera Therapeutics inc.
Federal Riding Name:
Mount Royal
Federal Riding Number:
24052
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110
Amendments: